Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial
Contemporary Clinical Trials · 2025
DOI: 10.1016/j.cct.2025.107887 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Mark J Giganti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Electronic address: mgiganti@sdac.harvard.edu. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Antibodies, Monoclonal, Humanized, Research Design, Clinical Trials, Phase III as Topic. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH.
Abstract (Originalsprache)
Seamless phase 2/3 study designs provide a framework for a more efficient trial. During the COVID-19 pandemic, such study designs were considered particularly appealing as there was an urgent global need to rapidly identify effective therapeutics. However, limited in vivo safety and efficacy data was available early in the pandemic to inform decisions. As part of the ACTIV-2 study, we implemented a phase 2/3 platform trial to evaluate multiple candidate treatments for non-hospitalized adults with COVID-19. In addition to an adequate safety profile, the decision to graduate an agent from phase 2 to phase 3 was based on showing treatment effects on clinical or laboratory markers. Decision criteria evolved over time as more data became available during the global pandemic. A seamless transition and approximately 20 % reduction in total sample size was achieved for one agent, amubarvimab plus romlusevimab. Using both simulation studies and actual results from graduation assessments of five ACTIV-2 candidate therapeutics, we provide a discussion of lessons learned from our implementation and recommendations for future seamless trials of interventions for emergent infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Electronic address: mgiganti@sdac.harvard.edu.
- David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA.
- Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
- University of North Carolina, Chapel Hill, NC 27599, USA.
- Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- National Institutes of Health, Rockville, MD 20852, USA.
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIH
Zitieren
APA
Giganti, M. J., Chew, K. W., Moser, C., Eron, J. J., Pinilla, M., Li, J. Z., Ritz, J., Javan, A. C., Wohl, D. A., Daar, E. S., Currier, J. S., Smith, D. M., Hughes, M. D., & ACTIV-2/A5401 Study Team (2025). Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.107887
Vancouver
Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, et al. Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial. Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2025.107887
BibTeX
@article{Giganti2025,
author = {Giganti, Mark J and Chew, Kara W and Moser, Carlee and Eron, Joseph J and Pinilla, Mauricio and Li, Jonathan Z and Ritz, Justin and Javan, Arzhang Cyrus and Wohl, David Alain and Daar, Eric S and Currier, Judith S and Smith, Davey M and Hughes, Michael D and ACTIV-2/A5401 Study Team, ACTIV-2/A5401 Study Team},
title = {Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial},
journal = {Contemporary Clinical Trials},
year = {2025},
doi = {10.1016/j.cct.2025.107887}
}
EUVIMED